• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of nursing and healthcare of chronic illness >Glargine prescribing practices for Type 2 diabetes: is there room for improvement?
【24h】

Glargine prescribing practices for Type 2 diabetes: is there room for improvement?

机译：甘精胰岛素为2型糖尿病开处方的方法：还有改善的空间吗？

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Glargine prescribing practices for Type 2 diabetes: is there room for improvement? Aim. This study investigated Glargine prescribing practices at an outpatient clinic in a tertiary hospital. Background. Treatment outcomes for people with Type 2 diabetes have improved with the introduction of the basal insulin Glargine. However, to achieve optimal therapeutic results in a safe fashion, this insulin must be titrated in accordance with the manufacturer's recommendation. Method. Medical records of patients with Type 2 diabetes who had attended an outpatient clinic between 2007-2008 were reviewed. Data collected included the age and gender of the patient, whether the patient's insulin dose had been titrated, the Haemoglobin A1c (HbA1c) percentage on prescription of Glargine and follow-up HbA1c results and the time elapsed between the initial and follow-up HbAlc. Findings. Only 14.6% of all patients had their Glargine insulin prescription adjusted according to the manufacturer's recommendation. Despite this, prescription of Glargine insulin resulted in 43% of patients reducing their HbAlc result by at least 1%. Conclusion. Findings suggest that Glargine insulin was a contributing factor in the reduction of the patient's HbA1c. Relevance to clinical practice. This study indicates that Glargine insulin is not consistently prescribed as per the manufacturer's recommendation. Patient or clinician factors could explain why such a small percentage of patients had their Glargine prescription adjusted appropriately. Individualisation of Glargine insulin adjustment regimes, particularly in patients over the age of 75 years is vital to ensure positive patient outcomes.
机译：甘精胰岛素为2型糖尿病开处方的方法：还有改善的空间吗？目标。这项研究调查了一家三级医院门诊诊所的甘精胰岛素处方实践。背景。引入基础胰岛素甘精胰岛素可改善2型糖尿病患者的治疗效果。但是，为了以安全的方式获得最佳治疗效果，必须根据制造商的建议对该胰岛素进行滴定。方法。回顾了2007-2008年间在门诊就诊的2型糖尿病患者的病历。收集的数据包括患者的年龄和性别，患者的胰岛素剂量是否已滴定，甘精胰岛素处方中的血红蛋白A1c（HbA1c）百分比和后续的HbA1c结果以及初次HbAlc与后续HbAlc之间的时间间隔。发现。所有患者中只有14.6％的甘精胰岛素处方根据制造商的建议进行了调整。尽管如此，使用甘精胰岛素的处方仍使43％的患者将其HbAlc结果降低了至少1％。结论。研究结果表明，甘精胰岛素是降低患者HbA1c的一个促成因素。与临床实践有关。这项研究表明，根据制造商的建议，尚不能始终按需处方甘精胰岛素。患者或临床医生的因素可以解释为什么这么少的患者对他们的甘精胰岛素处方进行了适当的调整。甘精胰岛素调整方案的个性化，特别是在75岁以上的患者中，对于确保积极的患者预后至关重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号